Insulinotropic complex using an immunoglobulin fragment
US8476230B2 · kind B2 · utility
11Cited by
5References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 4, 2008 |
| Grant date | Jul 2, 2013 |
| Priority date | — |
| Expiry date | May 2, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and an immunoglobulin Fc region, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.